ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO473

Incidence of Thromboembolic Events Among Glomerular Disease Participants in the Cure Glomerulonephropathy Network (CureGN)

Session Information

Category: Glomerular Diseases

  • 1303 Glomerular Diseases: Clinical‚ Outcomes‚ and Trials


  • Khalid, Myda, Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana, United States
  • Mansfield, Sarah, Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States
  • Smith, Abigail R., Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States
  • Robinson, Bruce M., Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States
  • Abdelghani, Eman, Nationwide Children's Hospital, Columbus, Ohio, United States
  • Al-Uzri, Amira, Oregon Health & Science University, Portland, Oregon, United States
  • Bartosh, Sharon M., University of Wisconsin-Madison, Madison, Wisconsin, United States
  • Gipson, Debbie, University of Michigan, Ann Arbor, Michigan, United States
  • Kerlin, Bryce A., Nationwide Children's Hospital, Columbus, Ohio, United States
  • Rheault, Michelle N., University of Minnesota Medical School Twin Cities, Minneapolis, Minnesota, United States
  • Sperati, John, Johns Hopkins Medicine, Baltimore, Maryland, United States
  • Srivastava, Tarak, Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States
  • Wong, Craig S., University of New Mexico School of Medicine, Albuquerque, New Mexico, United States
  • Wadhwani, Shikha, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

Group or Team Name

  • CureGN ERO Writing Group

Thromboembolic (TE) events are well-known complications of glomerular disease, but incidence rates and risk factors are not well-defined. This analysis describes TE outcomes in CureGN, a prospective cohort study of adults and children with biopsy-proven minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN), or IgA nephropathy/vasculitis (IgA) from 65 US and 6 international sites.


Multivariable Cox regression was used to estimate associations with first post-enrollment TE event, among those without a prior event.


Among 2423 participants (566 MCD, 615 FSGS, 546 MN, 696 IgA), enrollment characteristics were: median age 31 yr (IQR 14-51), 35% children, 57% male, 13% Hispanic, 16% Black, median eGFR 83ml/min/1.73m2 (IQR 54-103), median UPCR 1.2 g/g (IQR 0.2-3.9). Median follow-up was 3.8 years (IQR 2.2-5.1). Overall, 46 participants (12 children, 34 adults) experienced at least one TE event, most commonly deep vein thrombosis, followed by pulmonary embolism. The cumulative incidence at 1-, 3-, and 5-years post-enrollment was 0.6%, 1.5%, and 1.8%, respectively, for children, and 1.9%, 3.3%, and 4.4%, respectively, for adults. First TE events were associated with Black race (HR=2.3, 95% CI=1.2-4.5) and lower serum albumin ((HR=0.67 per g/dL, 95% CI=0.47-0.94), as well as with older age, tobacco use, higher body mass index, and lower eGFR [Figure]. Glomerular disease subtype was not associated with TE events (p=0.74).


TE events frequently complicate glomerular disease and in this cohort were associated with with particular demographic and clinical characteristics. Additional data will extend understanding of thromboembolic risk in patients with glomerular disease and inform practice guidelines.

Cox regression models for time to thromboembolic event


  • NIDDK Support